U.S. Markets open in 4 hrs 35 mins
S&P Futures
2,477.50
+4.25 (+0.17%)Dow Futures
21,676.00
+30.00 (+0.14%)
| Previous Close | 72.52 |
| Open | 72.37 |
| Bid | 71.91 x 100 |
| Ask | 73.75 x 200 |
| Day's Range | 71.95 - 72.69 |
| 52 Week Range | 55.06 - 75.04 |
| Volume | 4,876,980 |
| Avg. Volume | 5,545,355 |
| Market Cap | 115.53B |
| Beta | 1.43 |
| PE Ratio (TTM) | 18.82 |
| EPS (TTM) | 3.86 |
| Earnings Date | Jul 28, 2017 |
| Dividend & Yield | 2.56 (3.53%) |
| Ex-Dividend Date | 2017-07-12 |
| 1y Target Est | 75.41 |
- Motley Fool•9 hours ago
Gilead Sciences Has 3 Available Options, but Only 1 Makes Sense
Gilead should cut itself in two. Here's why.
- Reuters•11 hours ago
Gilead Sciences profit falls, but beats Wall Street estimates
Gilead Sciences Inc on Wednesday reported lower second-quarter profits as use of its flagship hepatitis C drugs continued to decline, but the results still beat Wall Street estimates and the company raised its full-year sales outlook. After one-time items, Gilead earned $2.56 a share. Wall Street analysts, on average, had forecast adjusted earnings of $2.15 a share, according to Thomson Reuters I/B/E/S.
- Accesswire•2 days ago
AbbVie Several Candidates to Replace Humira in the Pipeline
NEW YORK, NY / ACCESSWIRE / July 25th, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...
